C. Mainor

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane

C. Isaacs, M. Tan, S. Swain, 2022, Breast Cancer Research and Treatment.

Risk Management for BRCA1/BRCA2 Mutation Carriers Without and With Breast Cancer

C. Isaacs, C. Mainor, 2020, Current Breast Cancer Reports.

A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.

C. Isaacs, P. Pohlmann, F. Lynce, 2023, Contemporary clinical trials communications.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2024, Nature communications.

Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

E. Stringer-Reasor, S. Tolaney, C. Jochems, 2023, medRxiv.